AR: FDA is looking into the safety and effectiveness of biphasic defibrillators used for cardioversion and defibrillation in order to understand the conditions that affect their performance.
MB: Over the past three years, FDA has received reports of 14 events in which a 200 joule biphasic defibrillator was ineffective in terminating an arrhythmia, whereas a subsequent shock from a 360 joule device resulted in immediate defibrillation or cardioversion. The majority of these events occurred during attempts at cardioversion of atrial fibrillation, but there was at least one instance of attempted defibrillation of a ventricular arrhythmia.
AR: It's important to emphasize that FDA's analysis of these cases does not suggest the need for any change in current clinical practice. Clinicians and first responders should continue to use the defibrillators they already have. But to help us better understand this issue, we're asking healthcare professionals to report instances where it took shocks from two different devices to defibrillate or cardiovert a patient.
MB: To find out the specific kinds of information your report should contain, and to get instructions on how to submit a report, go to our website.

标题
Biphasic Defibrillator Energy Levels (FDA)

视频介绍
FDA Patient Safety News - January, 2010 - Show #94
FDA is looking into the safety and effectiveness of biphasic defibrillators used for cardioversion and defibrillation in order to understand the conditions that affect their performance.